- Home
- » Tags
- » Ustekinumab
Top View
- INN Working Document 05.179 Update 2011
- STELARA® (Ustekinumab) Injection, for Subcutaneous Or Intravenous Use Subcutaneous Injection Initial U.S
- (INN) for Biological and Biotechnological Substances
- (Ustekinumab) Draft USPI STN: BL 125261/1 30 December, 2009
- EAACI IG Biologicals Task Force Paper on the Use of Biologic Agents in Allergic Disorders O
- Rxoutlook® 3Rd Quarter 2020
- Dendritic Cell-Mediated Th2 Immunity and Immune Disorders
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab
- Clinical Rx Forum Volume 5 Issue 2
- Secukinumab Emerges As a Rapidly Effective Therapy for Pityriasis Rubra Pilaris
- Tocilizumab Intravenous – (M0004)
- Phase II Multi-Centre, Double-Blind, Randomised Trial of Ustekinumab in Adolescents with New-Onset Type 1 Diabetes
- Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Medications That Are Immunosuppressive Or Immunomodulatory (This List Is Not All-Inclusive)
- Ustekinumab (Stelara) Is a Biologic Medication Medications
- A Pilot Study to Investigate Ustekinumab (STELARA®)
- Ustekinumab – Fact Sheet
- Ustekinumab (Stelara®) Is an Antibody That Blocks Specific Pro-Inflammatory Proteins (Cytokine) Called Interleukin-12 and Interleukin-23
- Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: a Narrative Review
- Atopic Dermatitis: Novel Therapeutic Targets and Pathways1 Full Abbreviations, Accreditation, and Disclosure Information Available at Peerview.Com/KCX40
- Datasheet: HCA210P Product Details
- VACCINE GUIDELINES for IMMUNOCOMPROMISED and OTHER SPECIAL POPULATIONS I. GENERAL PRINCIPLES COVID-19 Immunization Is Recommen
- WO 2013/087911 Al 20 June 2013 (20.06.2013) P O P C T
- Psoriatic Arthritis Agents
- Treatment of Atopic Dermatitis: What’S New?
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Supplementary Information
- Immunology; an Illustrated Outline; Sixth Edition
- STELARA Ustekinumab NEW ZEALAND DATA SHEET
- Appendix A: Dosing Regimens Modelled
- Prescribing Outlook New Medicines 2015
- Anticorps 120X90.Indd
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Hypersensitivity Reactions to Biological Drugs M Corominas,1 G Gastaminza,2 T Lobera3
- Stelara, INN-Ustekinumab
- Assessment Report : Stelara (Ustekinumab)
- Infliximab Combination for the Treatment of Severe Gastrointestinal Acute Gvhd
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Anti-P40 Antibodies Ustekinumab and Briakinumab
- (INN) for Biological and Biotechnological Substances
- 1 STELARA® (Ustekinumab) FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS and USAGE 1.1 Psoriasis (Ps) 1.2 Psoriatic Arthr
- Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
- Thalidomide - Wikipedia, the Free Encyclopedia
- Cimzia® (Certolizumab Pegol) – Oxford Clinical Policy
- (CNTO 1275) for the Treatment of Adult Patients with Chronic Moderate to Severe Plaque Psoriasis
- Eunethta JA2 WP7 DELIVERABLE
- Certolizumab Pegol (Cimzia) for Chronic Plaque Psoriasis in Adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112
- BILLING and CODING: COMPLEX DRUG ADMINISTRATION CODING (A58533) Links in PDF Documents Are Not Guaranteed to Work
- Compounds and Methods for Treating Inflammatory
- Inflammatory Conditions – Stelara® (Ustekinumab Intravenous Infusion)
- Population Pharmacokinetics of the Interleukin-23 Inhibitor
- (CIMZIA) in Psoriatic Arthritis Monograph
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- 761032Orig1s000
- Secukinumab for the Treatment of Plaque Psoriasis: a Review of Phase III Testing
- New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration
- Ocular Side Effects of Antirheumatic Medications: a Qualitative Review
- Hypersensitivity Reactions to Biologics (Part I)